Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

781.89 +30.69 (+4.09%)
Streaming Delayed Price Updated: 1:43 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 773,425
Open 764.49
Bid (Size) 781.22 (2)
Ask (Size) 782.67 (4)
Prev. Close 751.20
Today's Range 758.63 - 787.00
52wk Range 538.01 - 779.00
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report. 
Via Investor's Business Daily

Performance

YTD
+8.53%
+8.53%
1 Month
+8.53%
+8.53%
3 Month
+5.85%
+5.85%
6 Month
+27.15%
+27.15%
1 Year
+25.54%
+25.54%

More News

Read More
Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle
Via Benzinga
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
Via Benzinga
Regeneron Pharmaceuticals's Earnings Outlook
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Via Benzinga
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
The 7 Most Undervalued Stocks to Buy in February 2023
Via InvestorPlace
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Via InvestorPlace
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
Via InvestorPlace
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Via Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
Via Benzinga
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
Via Benzinga
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Via Talk Markets
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.